Glucotrack (Nasdaq:GCTK) announced today that it secured new intellectual property allowance protecting its continuous blood glucose monitor (CBGM).
The patent application, titled “Methods and Systems for Continuously Monitoring the Glucose Level of a Patient,” was allowed by the U.S. Patent and Trademark Office (USPTO), expanding the IP protecting the CBGM as Glucotrack looks to advance the technology toward commercialization.
Rutherford, New Jersey-based Glucotrack’s device features no on-body external component. The company aims to offer it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the blood. It aims to provide real-time readings without the lag time typically associated with interstitial glucose measurements.
Currently, Senseonics produces the only long-term, implantable CGM on the market — a one-year device.
Read more about the three-year CBGM device in a recent interview with Glucotrack CEO Paul V. Goode here.
Glucotrack said the filling adds to three CBGM patents issued in late 2025, further protecting the technologies across its sensor architecture.
Allowed claims cover implantable glucose monitoring systems that utilize an intravascular sensing lead coupled to an electronics assembly. That includes device architectures and methods designed to operate within the vasculature to support long-term glucose monitoring.
Glucotrack said the claims further encompass electrode configurations, lead-based sensing structures and associated implantation methods for continuous glucose measurement.
“This allowed application strengthens the protection around key elements of our CBGM, including novel sensor architectures designed to support long-term intravascular glucose monitoring,” said Paul V. Goode, president and CEO of Glucotrack. “Continuing to build our intellectual property is fundamental to our strategy as we advance the fully implantable system through clinical testing and toward commercialization.”
